N-pyrrolidinoacetamidine | 106500-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-pyrrolidinoacetamidine
• 英文别名: N,N-Tetramethylen-acetamidin；1-Pyrrolidin-1-ylethanimine
• CAS: 106500-97-4
• 化学式: C₆H₁₂N₂
• 分子量: 112.175
• InChiKey: LAILHIOPQOSEOS-UHFFFAOYSA-N

物化性质

• 沸点：
  141.6±23.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  27.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 乙腈 在 Ln(CF₃SO₃)3 作用下， 反应 96.0h， 生成 N-pyrrolidinoacetamidine
  参考文献：
  名称：

  Use of lanthanide(III) ions as catalysts for the reactions of amines with nitriles

  摘要：

  DOI：

  10.1021/jo00382a009

文献信息

• CATALYSTS AND METHODS FOR POLYMER SYNTHESIS
  申请人：NOVOMER, INC.

  公开号：US20130144032A1

  公开（公告）日：2013-06-06

  The present invention provides unimolecular metal complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to the active metal center of the complex.

  本发明提供了在二氧化碳和环氧化物的共聚合中具有增强活性的单分子金属配合物。还提供了使用这种金属配合物在合成聚合物中的方法。根据一个方面，本发明提供了包括与具有共催化活性的活化物种相耦合的多齿配体的金属配合物，该多齿配体与复合物的活性金属中心配位。
• Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
  申请人：Sinha Uma

  公开号：US20080153876A1

  公开（公告）日：2008-06-26

  Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.

  本文介绍了使用单位剂量因子Xa抑制剂化合物以及使用这些化合物抑制人类患者的血凝的方法。本文所披露的因子Xa抑制剂化合物的单位剂量，所需用于抑制灵长类动物的凝血作用，低于所需用于其他动物模型（如啮齿动物）获得类似凝血抑制水平的单位剂量。此外，本文还介绍了在体外试验中有用于预测人类体内抗血栓活性的方法。
• [EN] ß-LACTONE COMPOUNDS<br/>[FR] COMPOSÉS DE ß-LACTONE
  申请人：UNIV OXFORD INNOVATION LTD

  公开号：WO2019111020A1

  公开（公告）日：2019-06-13

  The present invention relates to certain β-lactone compounds that may be useful as inhibitors of bacterial beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of a bacterial infection.

  本发明涉及某些β-内酰胺类化合物，可用作细菌β-内酰胺酶的抑制剂。本发明还涉及制备这些化合物的过程，包括它们的制药组合物，并且涉及它们在治疗细菌感染中的使用。
• Inhibitors of factor Xa
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040116399A1

  公开（公告）日：2004-06-17

  Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

  本发明揭示了一种具有对哺乳动物因子Xa活性的新化合物、其盐和相关组合物。这些化合物在体外或体内用于预防或治疗凝血障碍。
• BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
  申请人：Zhu Bing-Yan

  公开号：US20090131411A1

  公开（公告）日：2009-05-21

  Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

  本发明涉及一种新型苯甲酰胺类化合物，包括其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物，具有对哺乳动物因子Xa的活性。本发明还涉及含有这种化合物的组合物。这些化合物和组合物在体内或体外用于预防或治疗凝血障碍。